Although the outcomes of transfers with cryopreserved blastocysts were not followed up for the BEYOND trial and the cumulative live birth rates and neonatal outcomes after cryotransfer are not known, clinicians could consider using a GnRH agonist trigger for potential high responders to maximize the chances of pregnancy and reduce the risk of OHSS by using a cryopreserved transfer. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.